---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-002893"
form_type: "8-K"
ticker: "AGPU"
cik: "0001446159"
company_name: "Axe Compute Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T22:52:14.722288+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Predictive Oncology Q1 net loss $4.2M on revenue $0.4M; cash $5.2M, EPS -$1.04

## Summary
- Net loss of ~$4.2M, wider than $3.5M loss in Q1 2023; diluted EPS -$1.04 vs -$0.86.
- Revenue $419,646, up 75% YoY from $239,895, driven by STREAMWAY system sales.
- Cash $5.2M at March 31, 2024, down from $8.7M at Dec 31, 2023.
- Abstract accepted at ASCO 2024 for ovarian cancer machine-learning survival model; collaboration with Fujifilm on endotoxin testing announced.
- FluGen collaboration for intranasal flu vaccine under $6.2M DoD grant progressing.

## SEC filing metadata
- accession: 0001171843-24-002893
- form_type: 8-K
- ticker: AGPU
- cik: 0001446159
- company_name: Axe Compute Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446159/000117184324002893/0001171843-24-002893-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446159/000117184324002893/f8k_051424.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-002893
- JSON: https://secwatch.observer/filing/0001171843-24-002893.json
- Plain text: https://secwatch.observer/filing/0001171843-24-002893.txt

## Key facts
- Earnings Releases
  Axe Compute Inc. reported the quarter ended March 31, 2024 results: revenue $419,646, net income net loss of approximately $4.2 million, EPS $(1.04).
  - Period: the quarter ended March 31, 2024
  - Revenue: $419,646
  - Net income: net loss of approximately $4.2 million
  - EPS: $(1.04)
  - Result: reported results
  source text: share for the quarter ended March 31, 2024, was $(1.04), compared to $(0.86) for the quarter ended March 31, 2023. Q1 2024 Financial Results: The company recorded revenue of $419,646 for the first quarter of 2024, compared to $239,895 for the comparable period in 2023. Revenues for the quarter ended March 31, 2024, and March 31, 2023, were primarily derived
  evidence_url: https://www.sec.gov/Archives/edgar/data/1446159/000117184324002893/0001171843-24-002893-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.